131 related articles for article (PubMed ID: 20197289)
1. Genetic variations in EGF and EGFR and glioblastoma outcome.
Sjöström S; Andersson U; Liu Y; Brännström T; Broholm H; Johansen C; Collatz-Laier H; Henriksson R; Bondy M; Melin B
Neuro Oncol; 2010 Aug; 12(8):815-21. PubMed ID: 20197289
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk.
Andersson U; Schwartzbaum J; Wiklund F; Sjöström S; Liu Y; Tsavachidis S; Ahlbom A; Auvinen A; Collatz-Laier H; Feychting M; Johansen C; Kiuru A; Lönn S; Schoemaker MJ; Swerdlow AJ; Henriksson R; Bondy M; Melin B
Acta Oncol; 2010 Aug; 49(6):767-75. PubMed ID: 20446891
[TBL] [Abstract][Full Text] [Related]
3. Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.
Jacobs DI; Liu Y; Gabrusiewicz K; Tsavachidis S; Armstrong GN; Zhou R; Wei J; Ivan C; Calin G; Molinaro AM; Rice T; Bracci PM; Hansen HM; Wiencke JK; Wrensch MR; Heimberger AB; Bondy ML
J Neurooncol; 2018 Jan; 136(1):33-39. PubMed ID: 28965162
[TBL] [Abstract][Full Text] [Related]
4. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
5. Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer.
Meng LQ
Tumour Biol; 2014 Dec; 35(12):12497-508. PubMed ID: 25217982
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
7. Association between epidermal growth factor (EGF) and EGF receptor gene polymorphisms and end-stage renal disease and acute renal allograft rejection in a Korean population.
Kim BW; Kim SK; Heo KW; Bae KB; Jeong KH; Lee SH; Kim TH; Kim YH; Kang SW
Ren Fail; 2020 Nov; 42(1):98-106. PubMed ID: 31906817
[No Abstract] [Full Text] [Related]
8. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease.
Bhowmick DA; Zhuang Z; Wait SD; Weil RJ
Cancer Res; 2004 Feb; 64(4):1220-3. PubMed ID: 14973082
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations in VEGF and VEGFR2 and glioblastoma outcome.
Sjöström S; Wibom C; Andersson U; Brännström T; Broholm H; Johansen C; Collatz-Laier H; Liu Y; Bondy M; Henriksson R; Melin B
J Neurooncol; 2011 Sep; 104(2):523-7. PubMed ID: 21191630
[TBL] [Abstract][Full Text] [Related]
10. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma.
Scheurer ME; Amirian E; Cao Y; Gilbert MR; Aldape KD; Kornguth DG; El-Zein R; Bondy ML
Clin Cancer Res; 2008 Oct; 14(20):6640-6. PubMed ID: 18927306
[TBL] [Abstract][Full Text] [Related]
12. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
13. SSBP2 variants are associated with survival in glioblastoma patients.
Xiao Y; Decker PA; Rice T; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Wiemels JL; Tihan T; Prados MD; Chang SM; Berger MS; Kosel ML; Fridley BL; Lachance DH; O'Neill BP; Buckner JC; Thompson RC; Nabors LB; Olson JJ; Brem S; Madden MH; Browning JE; Wiencke JK; Egan KM; Jenkins RB; Wrensch MR
Clin Cancer Res; 2012 Jun; 18(11):3154-62. PubMed ID: 22472174
[TBL] [Abstract][Full Text] [Related]
14. Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
Jain M; Kumar S; Upadhyay R; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Biol Ther; 2007 Oct; 6(10):1553-8. PubMed ID: 17912028
[TBL] [Abstract][Full Text] [Related]
15. Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.
Bieńkowski M; Piaskowski S; Stoczyńska-Fidelus E; Szybka M; Banaszczyk M; Witusik-Perkowska M; Jesień-Lewandowicz E; Jaskólski DJ; Radomiak-Załuska A; Jesionek-Kupnicka D; Sikorska B; Papierz W; Rieske P; Liberski PP
PLoS One; 2013; 8(6):e65444. PubMed ID: 23762372
[TBL] [Abstract][Full Text] [Related]
16. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
17. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.
Diedrich U; Lucius J; Baron E; Behnke J; Pabst B; Zoll B
J Neurol; 1995 Oct; 242(10):683-8. PubMed ID: 8568531
[TBL] [Abstract][Full Text] [Related]
18. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.
Vauleon E; Auger N; Benouaich-Amiel A; Laigle-Donadey F; Kaloshi G; Lejeune J; Delattre JY; Thillet J; Sanson M
Cancer Genet Cytogenet; 2007 Jan; 172(1):33-7. PubMed ID: 17175377
[TBL] [Abstract][Full Text] [Related]
19. Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.
da Silveira Fd; Lopes Bde A; da Fonseca CO; Quirico-Santos T; de Palmer Paixão IC; de Amorim LM
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1347-54. PubMed ID: 22481252
[TBL] [Abstract][Full Text] [Related]
20. Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer.
Upadhyay R; Jain M; Kumar S; Ghoshal UC; Mittal B
Oncol Res; 2008; 17(4):167-74. PubMed ID: 18773861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
